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LIPOCORTIN-1, lipocortin-2 and lipocortin-5 were
immunohistochemically assessed in rats. Apart from ani-
mals receiving no treatment, other animals received
pretreatment with methylprednisolone, or the 21-
aminosteroid U-74389F. Whereas Hpocortin immunore-
activity was absent in the greater part of the brain in
animals not pretreated with steroid (except in sporadic
microglial cells and choroid plexus), there was obvious
immunostaining of parenchymatous elements in steroid
pretreated animals. In the steroid pretreated animals
lipocortin immunoreactivity ofthe brain tissue may indi-
cate local formation of lipocortin under the influence of
steroids that had entered the tissue. The cellular elements
which showed immunostaining included meningeal
cells, neurones, ependyma, oligodendroglia and capillary
endotheHum.
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Introduction
Glucocorticosteroids have been shown clinically
to exert a dramatic effect on certain types of brain
oedema of vasogenic origin, i.e. brain oedema that
has been caused by leakage of blood plasma into
brain tissue due to breakdown of the blood-brain
barrier. In this respect, vasogenic brain oedema
resembles the inflammatory exudate in other parts of
the body, which in inflammatory lesions results from
the increase of vascular permeability. Blood-brain
barrier disruption often accompanies brain tumours,
traumatic lacerations, haemorrhages and infarctions,
and therefore brain oedema has a considerable clini-
cal significance, especially in view of the restricted
expansive capacity of the head, contributing to mor-
bidity and eventual mortality. 2,3 It has been shown
that the effect of glucocorticosteroids upon inflam-
mation is based upon the formation of lipocortins
(LET), proteins that inhibit the enzyme
phospholipase A2 .4,5 This enzyme is supposed to play
a role in inflammatory processes by liberating
arachidonic acid from membrane phospholipids,
while arachidonic acid is known to serve as a precur-
sor for eicosanoids (prostaglandins, leukotrienes and
lipoxins) which are considered as mediators of in-
flammation. Arachidonic acid has been measured in
increased amounts in brain tissue that has been
injured by various means, while arachidonic acid
itself has been shown to be capable of inducing brain
oedema, both in vitro and in vivo following its
intracerebral administration,e
Clinically, glucocorticosteroids have been shown
to exert a most beneficial influence in the clinical
treatment of tumour-associated oedema, where it is
effective in low dose. In contrast, they have been
shown to be ineffective in reducing mortality in brain
trauma, and to be of doubtful efficacy in stroke.
Currently, the group of 21-aminosteroid compounds
has been introduced that is supposed to exert a
similar protective effect on traumatized neural tissue
while lacking the other glucocorticoid effects.
Lipocortins (also called annexins) constitute a fam-
ily of proteins, the members of which have been
identified by analysis of the sequences. Lipocortins
1-5 (LeT 1-5) have in common a core with four
repeats of 70 amino acids, whereas the core of LeT-
6 contains eight repeats. It is the N-terminus that is
variable, being longest in LET-1 and decreasing in
length in the order of LET-2, LET-6, LET-3, LET-5 and
LET-4.1 Since the LeTs are polypeptides of
32-67 kDa they probably cannot cross the intact
blood-brain barrier. If they are to be assigned a role
in mediating the effects of glucocorticoids in brain
tissue, that should imply their local formation in the
blood-brain barrier or in the brain parenchyma.
Materials and Methods
The studies were performed on adult Wistar rats of
180 g mean body weight.
Steroids and dosage: Apart from untreated animals,
the animals consisted of a group treated with 2 mg/
kg of methylprednisolone, and a 21-aminosteroid (U-
74389F, Upjohn Co.; 10 mg/kg), the day before and
2 h before killing. The animals were killed by decapi-
tation, and the ipsilateral cerebral hemisphere was
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quickly frozen in Freon. Frozen sections of 5 btm
thickness were cut and treated with anti-lipocortin
antibody at 1:20 dilution.
Binding of antibody: Binding of antibody was
visualized by horseradish peroxidase-conjugated
swine anti-rabbit antibody (Dako, 1:40) developed
with 2-aminoethyl-carbazole+HiO2. The sections
were weakly counterstained with haematoxylin.
11 As
controls the samples were incubated with phosphate
buffered saline (PBS) as the first step.
Anti-lipocortin antibodies: The anti-lipocortin anti-
bodies were polyclonal antibodies that had been
raised in rabbits against either recombinant human
LCT-2, or the amino terminus peptides of LCT-1 and
LCT-5 (amino acids 15-31 for LCT-1, and amino acids
1-11 for LCT-5). For immunization the peptides
(1 mg/ml) were crosslinked to 400 btg keyhole limpet
haemocyanin by incubation with 0.5 ml of 20 mM
glutaraldehyde for 30 min at room temperature. In
Western blotting experiments the antibodies recog-
nized the different proteins with no cross reactivity.
Results
In the untreated, animals LCT-1 immunoreactivity
could not be observed in the greater part of the
brain, but only in sporadic cells, which are probably
of microglial nature (Fig. 1). The choroid plexus
showed a faint reaction (not shown). LCT-2 immuno-
staining was similar although less pronounced.
The rats pretreated with methylprednisolone
showed widespread LCT-1 immunoreactivity in neur-
ones, especially in those of the hippocampus, and
probably also in astrocytes as well as in microglial
cells (Fig. 2). Also, the choroid plexus showed
LCT-1 immunoreactivity.
Oligodendrocytes as well as capillary endothelial
cells were devoid of reaction product. LCT-2
immunostaining was less pronounced in the nervous
parenchyma, but was well demonstrable in the
choroid plexus and the leptomeninges (Fig. 3).
LCT-2 immunoreactivity was far less pronounced
than the reactivity to LCT-1, with the strongest reac-
tion seen in the meninges. The immunoreactivity to
LCT-5 was similar to that of LCT-1, being exhibited
most by microglia, the leptomeninges and also by
some blood vessels.
Pretreatment with the 21-aminosteroid gave the
strongest LCT-1 immunoreactivity in cortical neur-
ones, oligodendrogial cells of the white matter (Fig.
4), ventricular ependyma (Fig. 5) and choroid plexus
(Fig. 6). After the 21-aminosteroid pretreatment LCT-
2 immunoreactivity was evident also in cortical neur-
ones (Fig. 7), capillary endothelium, meningeal cells
and ventricular ependyma. The controls incubated
with PBS were all negative.
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FIG. 1. Absence of LCT-1 immunostaining in brain parenchyma, except of
sporadic microglia (arrows) in untreated uninjured animal. Bar, 10 lm.
FIG. 2. LCT-1 immunostaining of neurones in normal cerebral cortex of rat
treated with low-dose methylprednisolone. Bar, 10 m.
FIG. 3. LCT-2 immunostaining of leptomeninges in normal cerebral cortex
of rat treated with low-dose methylprednisolone. Bar, 10 m.
Discussion
There is strong enhancement of LTC ....
munoreactivity in the nervous parenchyma of the
glucocorticosteroid and 21-aminosteroid pretreated
animals in contrast to the absence of spontaneous
immunoreactivity in the majority of the brain ofBrain lipocortin immunoreactivity after steroid treatment
FIG. 4. LCT-1 immunoreactivity of rows of oligodendroglial cells in
subcortical white matter of rat treated with 21-aminosteroid. Bar, 10 m.
FIG. 5. LCT-1 immunostaining of ventricular ependyma of rat treated with
21-aminosteroid. Bar, 10 l.tm.
FIG. 6. LCT-1 immunostaining of choroid plexus of rat treated with 21-
aminosteroid. Bar, 10 l.tm.
untreated animals. Whereas in untreated animals
immunoreactivity was only localized in sporadic
microglial cells, the enhanced immunoreactivity in
steroid pretreated animals resided in neurones and
probably astrocytes as well, and in oligodendrocytes
in the 21-aminosteroid pretreated animals. The
choroid plexus consistently showed immunoreactiv-
FIG. 7. LCT-2 immunostaining of cortical neurones of rat treated with 21-
aminosteroid. Bar, 10 l.tm.
ity, even in animals not treated with steroid, as has
been reported previously.
12 As the choroid plexus is
one of the circumventricular organs possessing cap-
illaries devoid of barrier properties, there is a poss-
ibility that the immunostaining may reflect LCT of
systemic origin. Immunostaining of ventricular
ependymal cells as reported previously
12,13 was seen
after 21-aminosteroid pretreatment. Immun0reactiv-
ity to LCT-2 in capillary endothelium was only seen
after 21-aminosteroid pretreatment.
The results after steroid pretreatment clearly indi-
cate the ability of the steroids to cross the
blood-brain barrier, which was to be expected in
view of their lipophilicity. From the order of appear-
ance of immunostaining, it seems that the following
order of inducibility of LCT formation may be
derived: microglia, choroid plexus epithelium,
meningeal cells, neurone/astrocyte, ependyma,
oligodendroglia, capillary endothelium. The prefer-
ential effect of the steroids on microglia is well in
accordance with previous findings of a preferential
effect on macrophages. TM The immunoreactivity was
strongest for LCT-1 and less pronounced for LCT-2
and LCT-5.
Although the 21-aminosteroids have been reported
to exert no action upon glucose metabolism, they
had a strong effect in inducing LCT formation. In the
present study the steroids were administered 1 day
and 2 h prior to the experiment. Where dexa-
methasone had been administered to the animals
only 2 h before termination, the pattern of LCT
immunoreactivity was not different from that in un-
treated animals in that it was only observed in certain
regions, being absent in the larger part of the brain. 13
Although lately the effect of glucocorticosteroids
in suppressing eicosanoid formation has been ques-
tioned in a number of cell types, the effect has been
confirmed in macrophages, 14,15 to which the microglia
of the central nervous system may be considered
similar. It may be concluded that there is little spon-
taneous LCT immunoreactivity in the brain paren-
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chyma, and that glucocortico- and 21-aminosteroids
can induce LCT formation in the brain parenchyma,
and may in this way mediate the effects of steroids
in brain oedema.
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